{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:04:44Z","timestamp":1784178284799,"version":"3.55.0"},"reference-count":108,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2\u2013) metastatic breast cancer (MBC) is the most prevalent subtype of advanced breast cancer and is predominantly driven by estrogen receptor (ER) signaling. Endocrine therapy (ET) has become the backbone of first-line treatment; however, both intrinsic and acquired resistance limit long-term disease control. The introduction of cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitors has fundamentally reshaped the therapeutic landscape even in subsets of patients with aggressive or symptomatic visceral metastatic disease. Advances in molecular profiling have also enabled more precise, adaptive therapy. Circulating tumor DNA (ctDNA)-based liquid biopsy now allows real-time detection of emerging resistance mutations, particularly in ESR1. Additionally, patients with PIK3CA-mutated tumors who had progressed on or within 12 months of completing adjuvant ET and had no prior systemic therapy for metastatic disease had better treatment outcomes when treated with the PI3K inhibitor inavolisib in combination with palbociclib and fulvestrant. Together, these developments mark a shift from fixed treatment sequencing toward a more dynamic, biomarker-driven approach in first-line HR+\/HER2\u2013 MBC. Integration of CDK4\/6 inhibitors with next-generation endocrine agents and liquid biopsy-guided therapy offers the potential to delay resistance, improve survival outcomes, and individualize treatment.<\/jats:p>","DOI":"10.3390\/curroncol33070421","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T01:05:58Z","timestamp":1784077558000},"page":"421","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evolving First-Line Endocrine Therapy in HR+\/HER2\u2212 Metastatic Breast Cancer: CDK4\/6 Inhibition, Biomarker-Guided Strategies and Emerging Therapeutic Paradigms"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2833-6051","authenticated-orcid":false,"given":"Hikmat","family":"Abdel-Razeq","sequence":"first","affiliation":[{"name":"Section of Hematology and Medical Oncology, Department of Internal Medicine, King Hussein Cancer Center, Amman 11941, Jordan"},{"name":"School of Medicine, The University of Jordan, Amman 11942, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4368-1224","authenticated-orcid":false,"given":"Baha","family":"Sharaf","sequence":"additional","affiliation":[{"name":"Section of Hematology and Medical Oncology, Department of Internal Medicine, King Hussein Cancer Center, Amman 11941, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"ref_1","first-page":"e70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"dju055","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","article-title":"Mechanisms of endocrine resistance in breast cancer","volume":"62","author":"Osborne","year":"2011","journal-title":"Annu. Rev. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG), Davies, C., Godwin, J., Gray, R., Clarke, M., Cutter, D., Darby, S., McGale, P., Pan, H.C., and Taylor, C. (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet, 378, 771\u2013784.","DOI":"10.1016\/S0140-6736(11)60993-8"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2003.04.194","article-title":"Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group","volume":"21","author":"Mouridsen","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13058-023-01701-9","article-title":"Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+\/HER2\u2212 advanced breast cancer receiving first-line ribociclib plus fulvestrant","volume":"25","author":"Neven","year":"2023","journal-title":"Breast Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-3032","article-title":"Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+\/HER2- advanced breast cancer in MONALEESA-7: A phase III randomized clinical trial","volume":"28","author":"Lu","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Gao, Y., Yu, Y., Zhang, M., Yu, W., and Kang, L. (2024). Mechanisms of endocrine resistance in hormone receptor-positive breast cancer. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1448687"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13058-021-01462-3","article-title":"ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer","volume":"23","author":"Brett","year":"2021","journal-title":"Breast Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/ng.2822","article-title":"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer","volume":"45","author":"Toy","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2016.1279","article-title":"Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: A secondary analysis of the BOLERO-2 trial","volume":"2","author":"Chandarlapaty","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"bqaf127","DOI":"10.1210\/endocr\/bqaf127","article-title":"Emerging mechanisms of therapy resistance in metastatic ER+ breast cancer","volume":"166","author":"Truong","year":"2025","journal-title":"Endocrinology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","article-title":"ESR1 mutations\u2014A mechanism for acquired endocrine resistance in breast cancer","volume":"12","author":"Jeselsohn","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","article-title":"Analysis of circulating tumor DNA to monitor metastatic breast cancer","volume":"368","author":"Dawson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"102569","DOI":"10.1016\/j.ctrv.2023.102569","article-title":"Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?","volume":"117","author":"Corti","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s12282-017-0812-x","article-title":"Mechanism of resistance to endocrine therapy in breast cancer: The important role of PI3K\/Akt\/mTOR in estrogen receptor-positive, HER2-negative breast cancer","volume":"25","author":"Araki","year":"2018","journal-title":"Breast Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Fusco, N., Malapelle, U., Fassan, M., Marchi\u00f2, C., Buglioni, S., Zupo, S., Criscitiello, C., Vigneri, P., Dei Tos, A.P., and Maiorano, E. (2021). PIK3CA mutations as a molecular target for hormone receptor-positive, HER2-negative metastatic breast cancer. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.644737"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Ciruelos","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.3747\/co.25.3752","article-title":"Overcoming endocrine resistance in hormone receptor-positive breast cancer","volume":"25","author":"AlFakeeh","year":"2018","journal-title":"Curr. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10555-022-10023-9","article-title":"Heterogeneity and tumor evolution reflected in liquid biopsy in metastatic breast cancer patients: A review","volume":"41","author":"Kavan","year":"2022","journal-title":"Cancer Metastasis Rev."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Addanki, S., Meas, S., Sarli, V.N., Singh, B., and Lucci, A. (2022). Applications of circulating tumor cells and circulating tumor DNA in precision oncology for breast cancers. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23147843"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"313ra182","DOI":"10.1126\/scitranslmed.aac7551","article-title":"Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer","volume":"7","author":"Schiavon","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1038\/s41467-021-22605-2","article-title":"Genomic profile of advanced breast cancer in circulating tumour DNA","volume":"12","author":"Kingston","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10549-024-07376-w","article-title":"Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(\u2212) metastatic breast cancer: Prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice","volume":"207","author":"Bhave","year":"2024","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_26","first-page":"1382","article-title":"MYC induces CDK4\/6 inhibitor resistance by promoting pRB1 degradation","volume":"15","author":"Ma","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1158\/2159-8290.CD-18-0830","article-title":"PTEN loss mediates clinical cross-resistance to CDK4\/6 and PI3K\u03b1 inhibitors in breast cancer","volume":"10","author":"Costa","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/s41467-025-55914-x","article-title":"Real-world clinical multi-omics analyses reveal bifurcation of ER-independent and ER-dependent drug resistance to CDK4\/6 inhibitors","volume":"16","author":"Kan","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41523-021-00252-6","article-title":"Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort","volume":"7","author":"Grinda","year":"2021","journal-title":"npj Breast Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.clbc.2015.03.010","article-title":"Hormone receptor status and HER2 expression in primary breast cancer compared with synchronous axillary metastases or recurrent metastatic disease","volume":"15","author":"Rossi","year":"2015","journal-title":"Clin. Breast Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.annonc.2025.11.002","article-title":"Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer","volume":"37","author":"Cabel","year":"2026","journal-title":"Ann. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Fillbrunn, M., Signorovitch, J., Andr\u00e9, F., Wang, I., Lorenzo, I., Ridolfi, A., Park, J., Dua, A., and Rugo, H.S. (2022). PIK3CA mutation status, progression and survival in advanced HR+\/HER2\u2212 breast cancer: A meta-analysis of clinical trials. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-10078-5"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13058-020-1246-5","article-title":"ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis","volume":"22","author":"Zundelevich","year":"2020","journal-title":"Breast Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"74448","DOI":"10.18632\/oncotarget.12950","article-title":"Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer progressing on aromatase inhibitor","volume":"7","author":"Clatot","year":"2016","journal-title":"Oncotarget"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1056\/NEJMra1307118","article-title":"Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer","volume":"383","author":"Burstein","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: Abemaciclib as Initial Therapy for Advanced Breast Cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Gao, T., Sun, Y., Leng, P., Liu, D., Guo, Q., and Li, J. (2025). CDK4\/6 inhibitors in breast cancer therapy: Mechanisms of drug resistance and strategies for treatment. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1549520"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1470-2045(19)30804-6","article-title":"CDK4\/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: A US Food and Drug Administration pooled analysis","volume":"21","author":"Gao","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ajco.13555","article-title":"CDK4\/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care","volume":"17","author":"Hui","year":"2021","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Shao, H., Zhao, M., Guan, A.J., Shao, T., Zhou, D., Yu, G., and Tang, W. (2024). A network meta-analysis of efficacy and safety for first-line and second\/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer. BMC Med., 22.","DOI":"10.1186\/s12916-023-03238-2"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10549-020-05528-2","article-title":"Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: A meta-analysis of randomized clinical trials","volume":"180","author":"Li","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e943","DOI":"10.1016\/j.clbc.2018.04.017","article-title":"CDK4\/6 Inhibitors in Combination with Hormone Therapy for HR+\/HER2- Advanced Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials","volume":"18","author":"Deng","year":"2018","journal-title":"Clin. Breast Cancer"},{"key":"ref_45","unstructured":"National Comprehensive Cancer Network (2026, February 20). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1200\/JCO.21.01392","article-title":"Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update","volume":"39","author":"Burstein","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_47","first-page":"1307","article-title":"Management Strategies and Outcomes in HR+\/HER2\u2212 Metastatic Breast Cancer Receiving CDK4\/6 Inhibitors and Subsequent Therapies","volume":"17","author":"Pogoda","year":"2025","journal-title":"Breast Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","article-title":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up","volume":"174","author":"Rugo","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/CM9.0000000000003151","article-title":"Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+\/HER2- advanced breast cancer: Final results of the randomized phase III MONARCH plus trial","volume":"138","author":"Hu","year":"2025","journal-title":"Chin. Med. J. (Engl.)"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","article-title":"MONARCH 3 final PFS: A randomized study of abemaciclib as initial therapy for advanced breast cancer","volume":"5","author":"Johnston","year":"2019","journal-title":"npj Breast Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: Abemaciclib in Combination with Fulvestrant in Women with HR+\/HER2\u2212 Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.23.00137","article-title":"Overall Survival with Palbociclib Plus Letrozole in Advanced Breast Cancer","volume":"42","author":"Slamon","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer","volume":"381","author":"Im","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/oncolo\/oyac205","article-title":"Palbociclib with fulvestrant or letrozole in endocrine-sensitive patients with HR-positive\/HER2-negative advanced breast cancer: A detailed safety analysis of the randomized PARSIFAL trial","volume":"28","author":"Bellet","year":"2023","journal-title":"Oncologist"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.24.00144","article-title":"Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women with Clinically Aggressive Hormone Receptor-Positive\/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer","volume":"42","author":"Lu","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Loibl, S., Thill, M., Rey, J., Rautenberg, B., Bjelic-Radisic, V., Decker, T., Rom, J., K\u00f6gel, M., L\u00fcbbe, K., and Nacke, A. (2025). Abstract LB1-03: Primary results of the randomised Phase III trial comparing first-line ET plus palbociclib vs standard mono-chemotherapy in women with high risk HER2\u2212\/HR+ metastatic breast cancer and indication for chemotherapy\u2014PADMA study. Clin. Cancer Res., 31.","DOI":"10.1158\/1557-3265.SABCS24-LB1-03"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1007\/s12672-025-02699-6","article-title":"Should CDK4\/6 inhibitors replace chemotherapy in HR+ \/HER2\u2212 metastatic breast cancer with visceral crisis? Evaluating the emerging evidence","volume":"16","author":"Orlandi","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_63","unstructured":"(2026, February 16). ClinicalTrials.gov. ABIGAIL Trial: Abemaciclib, ET \u00b1 Paclitaxel in Aggressive HR+\/HER2\u2212 MBC. NCT04603183, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04603183."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"S1215","DOI":"10.1016\/j.annonc.2024.08.2261","article-title":"LBA23 ABIGAIL: Randomized phase II study of abemaciclib plus endocrine therapy (ET) with or without a short course of induction paclitaxel in patients (pts) with previously untreated HR-positive\/HER2-negative advanced breast cancer (HR+\/HER2\u2212 ABC) with aggressive disease criteria","volume":"35","author":"Cortes","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/annonc\/mdw139","article-title":"Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: Patient-reported outcomes from the PALOMA-3 trial","volume":"27","author":"Harbeck","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e1346","DOI":"10.1634\/theoncologist.2020-0084","article-title":"Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2\u2212 Advanced Breast Cancer","volume":"25","author":"Goetz","year":"2020","journal-title":"Oncologist."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/14737140.2022.2052277","article-title":"Ribociclib efficacy in special populations and analysis of patient-reported outcomes in the MONALEESA trials","volume":"22","author":"Martorana","year":"2022","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1016\/S0140-6736(16)32389-3","article-title":"Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): An international, randomised, double-blind, phase 3 trial","volume":"388","author":"Robertson","year":"2016","journal-title":"Lancet"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s12282-018-0838-8","article-title":"Progression-free survival results in postmenopausal Asian women: Subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON)","volume":"25","author":"Noguchi","year":"2018","journal-title":"Breast Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10549-012-2192-4","article-title":"Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: Follow-up analysis from the randomized \u2018FIRST\u2019 study","volume":"136","author":"Robertson","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1634\/theoncologist.2015-0464","article-title":"Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer","volume":"22","author":"Kaklamani","year":"2017","journal-title":"Oncologist"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e7846","DOI":"10.1097\/MD.0000000000007846","article-title":"Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis","volume":"96","author":"Zhang","year":"2017","journal-title":"Medicine"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1177\/1758834017728928","article-title":"Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: Review","volume":"9","author":"Reinert","year":"2017","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1056\/NEJMoa1811714","article-title":"Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer","volume":"380","author":"Mehta","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Sharaf, B., Hajahjeh, A., Bani Hani, H., and Abdel-Razeq, H. (2024). Next generation selective estrogen receptor degraders in postmenopausal women with advanced-stage hormone receptor-positive, HER2-negative breast cancer. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1385577"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Neupane, N., Bawek, S., Gurusinghe, S., Ghaffary, E.M., Mirmosayyeb, O., Thapa, S., Falkson, C., O\u2019Regan, R., and Dhakal, A. (2024). Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer. Cancers, 16.","DOI":"10.3390\/cancers16030619"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Huang, X., Yu, Y., Luo, S., Fu, W., Zhang, J., and Song, C. (2024). The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on \u2265 1 line of endocrine therapy: Systematic review and meta-analysis. BMC Cancer, 24, Erratum in BMC Cancer 2024, 24, 205.","DOI":"10.1186\/s12885-023-11722-4"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1158\/1078-0432.CCR-23-1796","article-title":"Phase Ia\/b Study of Giredestrant \u00b1 Palbociclib and \u00b1 Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced\/Metastatic Breast Cancer","volume":"30","author":"Jhaveri","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"LBA1006","DOI":"10.1200\/JCO.2026.44.17_suppl.LBA1006","article-title":"Giredestrant (GIRE) + palbociclib (PALBO) vs letrozole (LET) + PALBO as first-line (1L) therapy in patients (pts) with estrogen receptor\u2013positive, HER2-negative locally advanced or metastatic breast cancer (ER+, HER2\u2013 LA\/mBC): Primary analysis of the phase III persevERA BC trial","volume":"44","author":"Turner","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"S1561","DOI":"10.1016\/j.annonc.2025.09.026","article-title":"LBA16 Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2\u2013 aBC) previously treated with a CDK4\/6 inhibitor (i): Primary results of the phase III evERA BC trial","volume":"36","author":"Mayer","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Bardia, A., Schmid, P., Martin, M., Hurvitz, S., Jung, K., Rimawi, M., Saji, S., Werutsky, G., Harbeck, N., and Loi, S. (2025). Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial. SABCS, 32.","DOI":"10.1158\/1557-3265.SABCS25-GS1-10"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.annonc.2024.04.012","article-title":"A phase I dose escalation and expansion trial of the next generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA 1 monotherapy results","volume":"35","author":"Hamilton","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S1470-2045(24)00387-5","article-title":"Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): A multi-dose, open-label, randomised, phase 2 trial","volume":"25","author":"Oliveira","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"SERENA-6: First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","article-title":"Imlunestrant with or without Abemaciclib in Advanced Breast Cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_86","unstructured":"US National Library of Medicine (2026, June 17). A Study of Imlunestrant Versus Standard Adjuvant Endocrine Therapy in Patients with HR+\/HER2\u2212 Early Breast Cancer (EMBER-4). ClinicalTrials.gov Identifier: NCT05511779, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05514054."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3759179","DOI":"10.1155\/2020\/3759179","article-title":"A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+\/HER2\u2013 Metastatic Breast Cancer","volume":"2020","author":"Anderson","year":"2020","journal-title":"Int. J. Breast Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13058-020-01271-0","article-title":"Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: Targeting different nodes of the PI3K\/AKT\/mTORC1 pathway with different clinical implications","volume":"22","author":"Vernieri","year":"2020","journal-title":"Breast Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","article-title":"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: Final overall survival results from SOLAR-1","volume":"32","author":"Ciruelos","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e629","DOI":"10.1016\/S1470-2045(24)00673-9","article-title":"Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): One cohort of a phase 2, multicentre, open-label, non-comparative study","volume":"25","author":"Rugo","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib plus palbociclib and fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2501796","article-title":"Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer","volume":"393","author":"Jhaveri","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_93","unstructured":"US Food and Drug Administration (2026, March 24). FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine Resistant, PIK3CA Mutated, HR Positive, HER2 Negative Advanced Breast Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-inavolisib-palbociclib-and-fulvestrant-endocrine-resistant-PIK3CA-mutated-hr-positive."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41523-024-00626-6","article-title":"Circulating tumor DNA validity and potential uses in metastatic breast cancer","volume":"10","author":"Amato","year":"2024","journal-title":"npj Breast Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/annonc\/mdx483","article-title":"Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer","volume":"29","author":"Fribbens","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1158\/0008-5472.CAN-23-0694","article-title":"The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4\/6 Inhibitor Resistance","volume":"83","author":"Lawson","year":"2023","journal-title":"Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e055821","DOI":"10.1136\/bmjopen-2021-055821","article-title":"Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: Study design of PADA-1","volume":"12","author":"Berger","year":"2022","journal-title":"BMJ Open"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","article-title":"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): A randomised, open-label, multicentre, phase 3 trial","volume":"23","author":"Bidard","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_100","first-page":"663","article-title":"Endocrine therapy for advanced breast cancer: Evolving paradigms and precision medicine","volume":"14","author":"Turner","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant versus standard endocrine therapy for estrogen receptor-positive, HER2-negative advanced breast cancer (EMERALD)","volume":"40","author":"Bidard","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/OP.23.00830","article-title":"Current and Novel Treatment Options in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer","volume":"21","author":"Varma","year":"2025","journal-title":"JCO Oncol. Pract."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.annonc.2025.07.017","article-title":"Updated systemic treatment recommendations from ESMO MBC Living Guideline","volume":"36","author":"Trapani","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and HER2-negative metastatic breast cancer (TROPiCS-02): A randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1200\/JCO-24-02086","article-title":"Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4\/6 inhibition: Results from the phase III postMONARCH trial","volume":"43","author":"Kalinsky","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1200\/JCO.22.02392","article-title":"Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4\/6 inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer: MAINTAIN trial","volume":"41","author":"Kalinsky","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1200\/JCO.23.01940","article-title":"PACE: A randomized phase II study of fulvestrant, palbociclib, and avelumab after progression on cyclin-dependent kinase 4\/6 inhibitor and aromatase inhibitor for hormone receptor-positive\/HER2-negative metastatic breast cancer","volume":"42","author":"Mayer","year":"2024","journal-title":"J. Clin. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/7\/421\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:30:08Z","timestamp":1784176208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/7\/421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":108,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["curroncol33070421"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33070421","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]}}}